• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氧化应激与迟发性运动障碍:遗传药理学证据。

Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.

机构信息

Department of Psychiatry, Korea University College of Medicine, Seoul, South Korea.

出版信息

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:207-13. doi: 10.1016/j.pnpbp.2012.10.018. Epub 2012 Oct 31.

DOI:10.1016/j.pnpbp.2012.10.018
PMID:23123399
Abstract

Tardive dyskinesia (TD) is a serious adverse effect of long-term antipsychotic use. Because of genetic susceptibility for developing TD and because it is difficult to predict and prevent its development prior to or during the early stages of medication, pharmacogenetic research of TD is important. Additionally, these studies enhance our knowledge of the genetic mechanisms underlying abnormal dyskinetic movements, such as Parkinson's disease. However, the pathophysiology of TD remains unclear. The oxidative stress hypothesis of TD is one of the possible pathophysiologic models for TD. Preclinical and clinical studies of the oxidative stress hypothesis of TD indicate that neurotoxic free radical production is likely a consequence of antipsychotic medication and is related to the occurrence of TD. Several studies on TD have focused on examining the genes involved in oxidative stress. Among them, manganese superoxide dismutase gene Ala-9Val polymorphisms show a relatively consistent association with TD susceptibility, although not all studies support this. Numerous pharmacogenetic studies have found a positive relationship between TD and oxidative stress based on genes involved in the antioxidant defense mechanism, dopamine turnover and metabolism, and other antioxidants such as estrogen and melatonin. However, many of the positive findings have not been replicated. We expect that more research will be needed to address these issues.

摘要

迟发性运动障碍(TD)是长期使用抗精神病药物的严重不良反应。由于存在发生 TD 的遗传易感性,并且在药物治疗的早期阶段之前或期间难以预测和预防其发展,因此对 TD 的药物遗传学研究很重要。此外,这些研究增强了我们对异常运动障碍(如帕金森病)遗传机制的了解。然而,TD 的病理生理学仍然不清楚。TD 的氧化应激假说就是 TD 的可能病理生理模型之一。TD 的氧化应激假说的临床前和临床研究表明,神经毒性自由基的产生可能是抗精神病药物治疗的结果,并与 TD 的发生有关。几项关于 TD 的研究集中在检查涉及氧化应激的基因上。其中,锰超氧化物歧化酶基因 Ala-9Val 多态性与 TD 易感性有相对一致的关联,尽管并非所有研究都支持这一点。许多药物遗传学研究基于涉及抗氧化防御机制、多巴胺转化和代谢以及其他抗氧化剂(如雌激素和褪黑素)的基因,发现 TD 与氧化应激之间存在正相关关系。然而,许多阳性发现并未得到复制。我们预计需要进行更多的研究来解决这些问题。

相似文献

1
Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.氧化应激与迟发性运动障碍:遗传药理学证据。
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:207-13. doi: 10.1016/j.pnpbp.2012.10.018. Epub 2012 Oct 31.
2
Free radicals, antioxidant defense systems, and schizophrenia.自由基、抗氧化防御系统与精神分裂症。
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:200-6. doi: 10.1016/j.pnpbp.2013.02.015. Epub 2013 Mar 5.
3
Genetics of tardive dyskinesia.迟发性运动障碍的遗传学。
Int Rev Neurobiol. 2011;98:231-64. doi: 10.1016/B978-0-12-381328-2.00010-9.
4
[Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].抗精神病药物所致迟发性运动障碍的药物遗传学评估:5-羟色胺2C受体基因以及多巴胺D3变异等位基因(甘氨酸)与锰超氧化物歧化酶野生等位基因(缬氨酸)组合的作用
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2003 Apr;20(2):98-102.
5
Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes.迟发性运动障碍中的氧化应激:NADPH 醌氧化还原酶 1(NQO1)和超氧化物歧化酶 2(SOD2,MnSOD)基因的遗传关联研究和荟萃分析。
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):50-6. doi: 10.1016/j.pnpbp.2009.09.020. Epub 2009 Sep 22.
6
[Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland].[波兰中部患有迟发性运动障碍的精神分裂症患者的锰超氧化物歧化酶基因(MnSOD)多态性]
Psychiatr Pol. 2006 Sep-Oct;40(5):937-48.
7
Oxidative stress and therapeutic implications in psychiatric disorders.氧化应激与精神障碍的治疗意义。
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:197-9. doi: 10.1016/j.pnpbp.2013.03.003. Epub 2013 Mar 21.
8
Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population.锰超氧化物歧化酶Ala-9Val多态性与科萨族人群精神分裂症及异常不自主运动发生之间的关联
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):664-72. doi: 10.1016/j.pnpbp.2006.12.019. Epub 2007 Jan 12.
9
Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.SLC18A2 基因与迟发性运动障碍的关联研究。
J Psychiatr Res. 2013 Nov;47(11):1760-5. doi: 10.1016/j.jpsychires.2013.07.025. Epub 2013 Sep 6.
10
Mn-superoxide dismutase activity is associated with orofacial involuntary movements in schizophrenia patients with tardive dyskinesia.锰超氧化物歧化酶活性与迟发性运动障碍的精神分裂症患者的口面部不自主运动有关。
Hum Psychopharmacol. 2015 Jan;30(1):57-63. doi: 10.1002/hup.2453.

引用本文的文献

1
Geraniin Ameliorates Haloperidol-Induced Orofacial Dyskinesia in Rats Through Mitigating Neuronal Oxidative Stress, Neuroinflammation, and Apoptosis via Modulation of the Nrf2 Signaling Pathway.香叶木素通过调节Nrf2信号通路减轻神经元氧化应激、神经炎症和细胞凋亡,改善大鼠氟哌啶醇诱导的口面部运动障碍。
Int J Mol Sci. 2025 Jun 6;26(12):5458. doi: 10.3390/ijms26125458.
2
Unique and overlapping mechanisms of valbenazine, deutetrabenazine, and vitamin E for tardive dyskinesia.丙戊嗪、氘代丁苯那嗪和维生素E治疗迟发性运动障碍的独特及重叠机制
Schizophrenia (Heidelb). 2025 Apr 23;11(1):69. doi: 10.1038/s41537-025-00618-w.
3
A single dose of haloperidol decanoate induces short-term hippocampal neuroinflammation: focus on the glial response.
单次注射癸酸氟哌啶醇可诱发短期海马神经炎症:聚焦于神经胶质反应。
Pharmacol Rep. 2025 Jun;77(3):800-808. doi: 10.1007/s43440-025-00706-9. Epub 2025 Feb 21.
4
Safety assessment of deutetrabenazine: real-world adverse event analysis from the FAERS database.氘代丁苯那嗪的安全性评估:来自FAERS数据库的真实世界不良事件分析
Front Pharmacol. 2024 Dec 23;15:1498215. doi: 10.3389/fphar.2024.1498215. eCollection 2024.
5
Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis.精神分裂症或心境障碍患者迟发性运动障碍药物干预的疗效和可接受性:一项系统评价和网状Meta分析
Mol Psychiatry. 2025 Mar;30(3):1207-1222. doi: 10.1038/s41380-024-02733-z. Epub 2024 Dec 18.
6
Effects of Acute Haloperidol Treatment on Dopaminergic Markers, GAD and A Receptors in Rats with High and Low VCMs.急性氟哌啶醇处理对高 VCMs 和低 VCMs 大鼠多巴胺能标志物、GAD 和 A 受体的影响。
Neurochem Res. 2024 Nov 14;50(1):4. doi: 10.1007/s11064-024-04275-w.
7
Molecular and Behavioral Neuroprotective Effects of Clavulanic Acid and Crocin in Haloperidol-Induced Tardive Dyskinesia in Rats.克拉维酸和藏红花素对大鼠氟哌啶醇诱导的迟发性运动障碍的分子和行为神经保护作用
Mol Neurobiol. 2025 Apr;62(4):5156-5182. doi: 10.1007/s12035-024-04566-x. Epub 2024 Nov 9.
8
Vitexin Mitigates Haloperidol-Induced Orofacial Dyskinesia in Rats through Activation of the Nrf2 Pathway.牡荆素通过激活 Nrf2 通路减轻大鼠氟哌啶醇诱导的口面部运动障碍。
Int J Mol Sci. 2024 Sep 23;25(18):10206. doi: 10.3390/ijms251810206.
9
for Tardive Dyskinesia and Plasma Activity: Association with Ala-9Val Variant: A Randomized, Double-blind Trial.用于迟发性运动障碍和血浆活性:与 Ala-9Val 变体的关联:一项随机、双盲试验。
Curr Neuropharmacol. 2024;22(14):2443-2452. doi: 10.2174/1570159X22666240530095721.
10
Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic Treatments.用于抗精神病药物治疗个体化的药物基因组学的临床效用与实施
Pharmaceutics. 2024 Feb 7;16(2):244. doi: 10.3390/pharmaceutics16020244.